Abbott Laboratories $ABT Shares Sold by Burling Wealth Partners LLC

Burling Wealth Partners LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 5.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,389 shares of the healthcare product maker’s stock after selling 5,071 shares during the quarter. Abbott Laboratories comprises 1.4% of Burling Wealth Partners LLC’s holdings, making the stock its 22nd largest position. Burling Wealth Partners LLC’s holdings in Abbott Laboratories were worth $8,459,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ABT. Nia Impact Advisors LLC increased its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the period. Park Place Capital Corp lifted its stake in Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after acquiring an additional 81 shares during the period. Clayton Financial Group LLC boosted its holdings in shares of Abbott Laboratories by 1.4% in the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after acquiring an additional 84 shares during the last quarter. Jamison Private Wealth Management Inc. increased its stake in shares of Abbott Laboratories by 0.5% in the fourth quarter. Jamison Private Wealth Management Inc. now owns 15,854 shares of the healthcare product maker’s stock worth $1,986,000 after acquiring an additional 85 shares during the period. Finally, Raleigh Capital Management Inc. increased its stake in shares of Abbott Laboratories by 3.9% in the fourth quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock worth $287,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Bank of America decreased their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Benchmark reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a report on Friday. Argus lowered their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Raymond James Financial dropped their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Stock Up 1.0%

ABT opened at $101.72 on Tuesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a fifty day moving average of $90.28 and a two-hundred day moving average of $101.84. The stock has a market capitalization of $177.18 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.